Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology, hematology, cardiology and women's health with an initial focus in ovarian cancer. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.
Forward Looking Statements
This news release contains forward-looking statements that involve
significant risks and uncertainties, including statements regarding
Vermillion's plans, objectives, expectations and intentions. These forward-
looking statements are based on Vermillion's current expectations. The
Private Securities Litigation Reform Act of 1995 provides a "safe harbor"
for such forward-looking statements. In order to comply with the terms of
the safe harbor, Vermillion notes that a variety of factors could cause
actual results and experience to differ materially from the anticipated
results or other expectations expressed in such forward-looking statements.
Factors that could cause actual results to materially differ include but
are not limited to: (1) uncertainty in obtaining intellectual property
protection for inventions made by Vermill
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved